Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706536 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
NCT01706536 is a Phase 2 study that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 275 participants.
The verdict
NCT01706536, a Phase 2 study, has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel arm study. The study population will consist of subjects, 35 to 75 years of age, with a diagnosis of moderate to severe COPD per Global Initiative for Chronic Obstructive Lung Disease guidelines.
Interventions
- DRUG Placebo
- DRUG EP-101 12.5 mcg
- DRUG EP-101 25 mcg
- DRUG EP-101 50 mcg
- DRUG EP-101 100 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01706536
The ClinicalTrials.gov registry entry for NCT01706536 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunovion Respiratory Development, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01706536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01706536 about?
NCT01706536 is a clinical study titled "A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease". This is a randomized, double-blind, placebo-controlled, parallel arm study. The study population will consist of subjects, 35 to 75 years of age, with a diagnosis of moderate to severe COPD per Global Initiative for Chronic Obstructive Lung Disease guidelines.
What is the current status of trial NCT01706536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2012-10. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01706536?
The interventions under investigation include: Placebo (DRUG), EP-101 12.5 mcg (DRUG), EP-101 25 mcg (DRUG), EP-101 50 mcg (DRUG), EP-101 100 mcg (DRUG).
Who is sponsoring clinical trial NCT01706536?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.